Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03460600Completed

Vitreo-papillary Traction as an Entity Identified by Optical Coherence Tomography (OCT).

Role: lead

NCT03316092Completed

Monitoring and Preventing Hydroxychloroquine, Plaquenil, Toxicity.

Role: lead

NCT03087682Completed

Pituitary Gland Enlargement Was First Diagnosed by Optical Coherence Tomography (OCT)

Role: lead

NCT03068702Completed

New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA)

Role: lead

All 4 trials loaded